Heron Therapeutics, Inc.

NASDAQ:HRTX

Biotechnology

Healthcare
$0.27 +3.74%

+$0.01 today

Market cap
$51.94M
Beta
1.57
P/E (TTM)
-2.5
EPS (TTM)
-$0.16
52W Low $0.38High $2.30

Volume 1.81M

Average 2.90M

HRTX EBITDA Margin

EBITDA as a percentage of revenue.

Heron Therapeutics, Inc.NASDAQ: HRTX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -21.8%

EBITDA Margin was -21.8% in Q1 FY2026, down 31.3 pp from a year earlier. On a trailing-twelve-month basis it was -16.0%, down 16.3 pp year over year. Over 3 fiscal years it widened by 152.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -11.9% for the fiscal year ending Dec 2026, down from -11.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-21.8%-19.9 pp QoQ
Last fiscal yearDec 2025
-11.5%-8.0 pp YoY
LTMMar 2026
-16.0%-16.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-31.3 pp+3.6 pp+34.9 pp
1 year-8.0 pp-0.4 pp+7.6 pp
3 years+152.5 pp+7.6 pp-144.9 pp
5 years+18.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-11.5%
Year-over-year change
-8.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How HRTX compares with its peers on the latest reported figures

  • HRTX's LTM Mar 2026 EBITDA Margin of -16.0% is the 2nd highest of the 7 companies compared; the peer median is -126.3%.
  • Its year-over-year change of -16.3 pp is the 5th highest of 6, against a peer median of +24.2 pp.
  • Over three fiscal years its change of +152.5 pp compares with a peer median of -141.6 pp.
HRTX Competitors Peer median
EBITDA Margin for HRTX and competitors
Company Period LTM level YoY 3-year change
PLXProtalix BioTherapeutics, Inc.LTM Mar 202629.2% +17.2 pp+17.0 pp
HRTXHeron Therapeutics, Inc.LTM Mar 2026-16.0% -16.3 pp+152.5 pp
MDWDMediWound Ltd.LTM Mar 2026-102.5% +24.2 pp-57.7 pp
OABIOmniAb, Inc.LTM Mar 2026-117.0% +50.4 pp-225.4 pp
IVVDInvivyd, Inc.LTM Mar 2026-135.5% +244.4 pp—
CHRSCoherus Oncology, Inc.LTM Mar 2026-341.0% -291.0 pp-282.5 pp
NTHINeonc Technologies Holdings, Inc.FY2025-149050.2% ——
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
TARAProtara Therapeutics, Inc.FY2025— ——
Peer median (excluding HRTX) -126.3%+24.2 pp-141.6 pp

Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue86.35M107.67M127.04M144.29M154.9M
Cost of Revenue46.02M54.87M65.11M38.65M41.35M
Gross Profit40.33M52.8M61.94M105.64M113.56M
Gross Margin46.7%49.0%48.8%73.2%73.3%
Research & Development130.82M82.7M39.13M16.68M12.43M
Selling, General & Admin127.33M144.75M119.82M100.48M103.67M
Operating Expenses258.15M227.46M172.55M117.17M116.1M
Depreciation & Amortization3.02M2.89M2.9M2.49M2.31M
EBITDA(215.25M)(176.66M)(103.79M)(5.06M)(17.88M)
EBITDA Margin-249.3%-164.1%-81.7%-3.5%-11.5%
Operating Income(217.83M)(174.66M)(110.62M)(11.53M)(2.54M)
Operating Margin-252.3%-162.2%-87.1%-8.0%-1.6%
Interest Income433K1.64M3.36M3.55M0
Interest Expense2.41M2.47M3.87M6.03M0
Other Income / Expenses(2.86M)(7.37M)56K(2.05M)(17.66M)
Income Before Tax(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Pre-Tax Margin-255.6%-169.1%-87.0%-9.4%-13.0%
Income Tax Expense00000
Net Income(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Net Margin-255.6%-169.1%-87.0%-9.4%-13.0%
EPS (Basic)(2.24)(1.67)(0.80)(0.09)(0.12)
EPS (Diluted)(2.24)(1.67)(0.80)(0.09)(0.12)
Weighted Avg Shares98.47M109M138.14M152.45M166.71M
Weighted Avg Shares (Diluted)98.47M109M138.14M152.45M166.71M

Heron Therapeutics, Inc.

NASDAQ:HRTX

Intrinsic Alpha fair value

Locked

Current Price

$0.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.